Multiple Sclerosis (MS)

Multiple Sclerosis (MS) is a chronic central nervous system disorder classified as an autoimmune disease. Unlike Motor Neuron Diseases (MND) such as ALS or SMA, or muscle disorders like Muscular Dystrophy (MD), MS arises when the immune system mistakenly attacks the protective sheath around nerve fibers — the myelin. This disrupts or slows nerve signal transmission. Unlike typical neurodegenerative diseases, MS damage is inflammation-mediated, and the disease course may be intermittent or progressive.

Overview

MS affects the brain, spinal cord, and optic nerves. Damage to myelin produces multiple hardened plaques (scars), hence the name “multiple sclerosis.” These lesions interfere with nerve signaling, causing diverse symptoms. MS most often occurs in young adults aged 20–40, with women affected 2–3 times more than men.

Types of MS

1. Relapsing-Remitting MS (RRMS)
   • Most common (≈85% of cases).
   • Symptoms flare suddenly (relapse), then partially or fully improve (remission).
   • Relapse intervals may last months to years.
2. Secondary Progressive MS (SPMS)
   • RRMS evolves into continuous worsening over time, with fewer relapses but increasing disability.
3. Primary Progressive MS (PPMS)
   • 10–15% of cases.
   • Symptoms steadily worsen from onset, without clear relapses/remissions.
4. Progressive-Relapsing MS (PRMS)
   • Rare.
   • Continuous progression with distinct relapses.

Symptoms

Symptoms vary depending on the affected nerves, but common features include:

• Sensory changes: numbness, tingling, burning (especially in limbs)
• Vision problems: blurred vision, double vision, optic neuritis (eye pain with vision loss)
• Motor issues: weakness, spasticity, poor coordination, unsteady gait
• Fatigue: persistent, abnormal tiredness
• Cognitive problems: memory loss, poor concentration
• Bladder/bowel dysfunction: incontinence, constipation
• Other: depression, dizziness, pain, sexual dysfunction

Symptoms may temporarily worsen with heat (Uhthoff’s phenomenon).

Causes

Exact cause unknown; likely a mix of genetic and environmental factors:

• Immune factors: T cells attack myelin, possibly triggered by viruses (e.g., EBV).
• Genetic predisposition: Not directly inherited, but family history increases risk (e.g., HLA-DR15 variant).
• Environmental factors:
  • Vitamin D deficiency (higher rates in low-sunlight regions like Northern Europe)
  • Geography (more common farther from the equator)
  • Smoking (increases risk and progression)

MS is not purely degenerative; it is immune-mediated, with potential for remyelination or repair.

Diagnosis

Diagnosis requires evidence of nerve damage across time and space (“multiple” lesions). Methods include:

• MRI: detects brain/spinal cord plaques
• Lumbar puncture: identifies oligoclonal bands in cerebrospinal fluid
• Evoked potentials: measure nerve conduction speed (e.g., visual evoked potentials)
• Clinical criteria: McDonald diagnostic criteria combining symptoms and imaging

Other conditions (e.g., neurosyphilis, vitamin B12 deficiency) must be excluded.

Treatment

No cure; treatment focuses on acute relapse control, slowing progression, and symptom management:

1. Acute relapse therapy
   • Steroids (e.g., methylprednisolone) shorten relapse duration
2. Disease-modifying therapies (DMTs)
   • Injections: Interferon Beta, Ofatumumab
   • Oral drugs: Fingolimod, Teriflunomide, Dimethyl Fumarate, Cladribine, Siponimod (for SPMS)
   • Infusions: Natalizumab, Alemtuzumab, Ocrelizumab (for severe cases)

These suppress immune attacks and delay RRMS progression to SPMS.

3. Symptom management
   • Spasticity: Baclofen, physiotherapy
   • Fatigue: Modafinil, exercise programs
   • Neuropathic pain: Gabapentin
4. Rehabilitation
   • Physical therapy for mobility
   • Occupational therapy for daily living adaptation

Prognosis

Highly variable course:

• RRMS: may remain stable for years, some with minimal disability
• SPMS/PPMS: faster disability progression, late-stage wheelchair use common
• Lifespan shortened by 5–10 years on average, often due to complications (e.g., infections) rather than MS itself
• Early diagnosis and treatment greatly improve outcomes

Differences from Other Diseases

• MS vs. ALS: MS is immune-mediated myelin damage; ALS is motor neuron degeneration. MS has relapses/remissions; ALS is steadily progressive.
• MS vs. MD: MS affects the nervous system; MD directly damages muscle tissue.
• MS vs. SMA: MS is adult-onset and immune-related; SMA is genetic and infant-onset.

Latest Developments

• New drugs: Siponimod (SPMS option), BTK inhibitors (potential anti-inflammatory therapy)
• Stem cell therapy: Hematopoietic stem cell transplantation (HSCT) to reset the immune system, suitable for young severe cases
• Lifestyle: Vitamin D supplementation and healthy diet may slow progression

Update: 1/5/2026